More than 17,000 Physicians and Medical Scientists Against Covid Vaccination 世界で17000人の医師と医学者が子供のワクチン接種に反対

 

 Source: https://globalcovidsummit.org/news/thousands-of-physicians-and-scientists-reach-consensus-on-vaccinating-children-and-natural-immunity

WASHINGTON, DC, Jan. 21, 2022 -- Following Dr. Robert Malone’s appearance on The Joe Rogan Experience, more physicians and medical scientists have joined with their colleagues from around the world in signing the Physicians Declaration. Now with more than 17,000 signatures confirmed through a rigorous validation process, these physicians and scientists are represented by Dr. Malone as he speaks at the march to Defeat the Mandates on Sunday, January 23 in Washington, DC.

WASHINGTON, DC, January 21, 2022 -- ロバート・マローン博士の「ジョー・ローガン・エクスペリエンス」への出演を受け、より多くの医師や医学科学者が、世界中の同僚たちとともに、医師宣言に署名しています。現在、厳格な検証プロセスを経て17,000人以上の署名が確認されており、これらの医師・科学者は、1月23日（日）にワシントンDCで行われるDefeat the Mandatesへの行進で演説するマローン博士に代表されています。

The over 17,000 signers to the declaration have reached consensus on three foundational principles:

17,000人を超える署名者は、3つの基本原則について承諾しました。

1. Healthy children should not be subject to forced vaccination: they face negligible risk from covid, but face potential permanent, irreversible risk to their health if vaccinated, including heart, brain, reproductive and immune system damage.健康な子どもたちは、強制的なワクチン接種を受けるべきではありません。彼らは、コビドによるリスクは無視できますが、ワクチンを接種すると、心臓、脳、生殖、免疫系の損傷など、健康に永久的かつ不可逆的なリスクを負う可能性があるのです。
2. Natural Immunity Denial has prolonged the pandemic and needlessly restricted the lives of Covid-recovered people. Masks, lockdowns, and other restrictions have caused great harm especially to children and delayed the virus’ transition to endemic status.自然免疫の否定は、パンデミックを長引かせ、コビド回復者の生活を不必要に制限している。マスク、ロックダウン、その他の制限により、特に子供たちに大きな被害を与え、ウイルスの流行状態への終焉を遅らせています。
3. Health agencies and institutions must cease interfering with the physician-patient relationship. Policymakers are directly responsible for hundreds of thousands of deaths, as a result of institutional interference and blocking treatments proven to cure at a near 100% rate when administered early. 医療機関や団体は、医師と患者の関係に干渉することをやめなければならない。政策立案者は、制度的な干渉や、早期に投与すればほぼ100％の確率で治癒することが証明されている治療を阻害した結果、何十万人もの死に直接の責任を負っているのだ。

Staying loyal to the Hippocratic oath, the declaration’s signers have resisted financial inducements, threats, unprecedented censorship, and reputational attacks to remain committed first to patient health and well-being. After 23 months of research, millions of patients treated, hundreds of clinical trials performed and scientific data shared, and after demonstrating and documenting their success in combating COVID-19, the 17,000+ physicians and medical scientists who signed the declaration support the core principles Dr. Malone and many other doctors have been speaking out about since late last year.

忠誠をもって宣言の署名者は、金銭的誘惑、脅迫、前例のない検閲、風評攻撃に抵抗し、患者の健康と幸福を第一に考え続けてきたのです。23ヶ月の研究、何百万人もの患者の治療、何百もの臨床試験の実施と科学的データの共有、そしてCOVID-19との闘いにおける成功の実証と文書化を経て、宣言に署名した17000人以上の医師と医学者は、昨年末からマローン博士と他の多くの医師が発言している基本原則を支持しています。

The 17,000+ signatures of the declaration are authentic and must pass a screening process before being officially identified as signing the declaration. Signatories are required to supply their affiliation and a link to their medical organization, facility, or profile. Nurses, non-MD practitioners and non-medical scientists are removed from the list signatories, as are duplicate entries and “bot” emails. The emails of the signatories have been separately and repeatedly tested and verified by a 3rd-party provider. 

宣言の17,000人以上の署名は本物であり、宣言に署名したことが公式に確認される前に審査プロセスを通過しなければなりません。署名者は、所属と医療機関、施設、プロフィールへのリンクを提供することが義務付けられています。看護師、医学部以外の開業医、医学部以外の科学者は、重複入力や「ボット」メールと同様、署名者リストから除外されています。署名者の電子メールは、第3者プロバイダーによって個別に何度もテストされ、確認されています。

As the number of signatures to the declaration continues to rise, we have published a select group of world famous, highly credentialed physicians and scientists who authored the declaration. Many other doctors who have spoken out against the corruption, censorship and hypocrisy by authorities have been threatened, fired, censured, lied about, intimidated, and harassed - all while saving patients’ lives daily. Never has the public been forced to become lab rats, for a vaccine 5 years away from adequate testing, violating basic principles of informed consent. Moreover, the medical and scientific evidence on the efficacy and safety of the COVID-19 vaccine do not support mandating its use for anyone, especially healthy children.

宣言への署名が増え続ける中、宣言に署名した世界的に有名な高信頼性の医師や科学者を厳選して掲載しました。当局による腐敗、検閲、偽善に対して発言した他の多くの医師たちは、脅迫、解雇、問責、嘘、脅迫、嫌がらせを受けながら、日々患者の命を救っているのです。インフォームド・コンセントの基本原則に反し、十分な試験が行われていない5年後のワクチンのために、一般市民が実験台にさせられたことは一度もない。さらに、COVID-19ワクチンの有効性と安全性に関する医学的・科学的証拠は、誰にでも、特に健康な子どもたちにその使用を義務付けることを支持するものではありません。

January 23 March on Washington 

1月23日 ワシントン大行進 

The over 17,000 signers of the declaration will be represented on Sunday, January 23, when Dr. Malone stands with fellow doctors and scientists on stage in Washington DC, as part of the Defeat the Mandates march Sunday, January 23, 2022. At the Lincoln Memorial, they will be joined by a wide range of featured guests for a series of inspiring talks and musical performances. Join us!

宣言に署名した17,000人以上を代表して、マローン博士は、2022年1月23日（日）、ディフィート・ザ・マンデートの行進の一環として、ワシントンDCのステージに仲間の医師や科学者とともに立つ予定です。リンカーン記念館では、さまざまな著名なゲストとともに、刺激的な講演や音楽演奏が行われる予定です。ぜひご参加ください。

---

About the Global COVID Summitグローバルコロナサミットについて

Global Covid Summit is the product of an international alliance of doctors and scientists, committed to speaking truth to power about Covid pandemic research and treatment.

Global Covid Summitは、Covidパンデミックの研究と治療について権力に真実を語ることを約束した、医師と科学者の国際的な同盟から生まれたものです。

Thousands have died from Covid as a result of being denied life-saving early treatment. The Declaration is a battle cry from physicians who are daily fighting for the right to treat their patients, and the right of patients to receive those treatments - without fear of interference, retribution or censorship by government, pharmacies, pharmaceutical corporations, and big tech. We demand that these groups step aside and honor the sanctity and integrity of the patient-physician relationship, the fundamental maxim "First Do No Harm", and the freedom of patients and physicians to make informed medical decisions. Lives depend on it. More information here: https://globalCovidSummit.org

命を救う早期治療を拒否された結果、何千人もの人がコビドで亡くなっています。この宣言は、政府、薬局、製薬会社、ハイテク企業による干渉、報復、検閲を恐れることなく、患者を治療する権利、そして患者がそれらの治療を受ける権利を求めて日々戦っている医師たちの闘志を表しています。私たちは、これらの団体が身を引き、患者と医師の関係の神聖さと完全性、「まず害をなすなかれ」という基本原則、そして患者と医師が十分な情報を得た上で医療上の決定を行う自由を尊重することを求めます。生命はそれに依存しているのです。詳細はこちら： https://globalCovidSummit.org

---

 SUPPORTING EVIDENCE　エビデンス

Vaccinating Children

1. Deaths by Age U.S. : 0-18, Centers for Disease Control (CDC)
   
   
2. Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections, Petra Zimmermann, Nigel Curtis
   
   
3. SARS-CoV-2 mRNA Vaccination-Associated Myocarditis in Children Ages 12-17: A Stratified National Database Analysis, Tracy Beth Høeg, Allison Krug, Josh Stevenson, John Mandrola
   
   
4. Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units, Lara S. Shekerdemian, MD, MHA; Nabihah R. Mahmood, MD; Katie K. Wolfe, MD; et al.
   
   
5. State-Level Data on COVID-19 child mortality, American Academy of Pediatrics
   
   
6. Deaths in Children and Young People in England following SARS-CoV-2 infection during the first pandemic year: a national study using linked mandatory child death reporting data, C Smith, D Odd, R Harwood, J Ward, M Linney, M Clark, D Hargreaves, SN Ladhani, E Draper, PJ Davis, SE Kenny, E Whittaker, K Luyt, RM Viner, LK Fraser
   
   
7. Risk factors for intensive care admission and death amongst children and young people admitted to hospital with COVID-19 and PIMS-TS in England during the first pandemic year, J L Ward, R Harwood, C Smith, S Kenny, M Clark, PJ Davis, ES Draper, D Hargreaves, S Ladhani, M Linney, K Luyt, S Turner, E Whittaker, L K Fraser, R.M Viner
   
   
8. Shedding of Infectious SARS-CoV-2 Despite Vaccination, Kasen K. Riemersma, Brittany E. Grogan, Amanda Kita-Yarbro, Peter J. Halfmann, Hannah E. Segaloff, Anna Kocharian, Kelsey R. Florek, Ryan Westergaard, Allen Bateman, Gunnar E. Jeppson, Yoshihiro Kawaoka, David H. O’Connor, Thomas C. Friedrich, Katarina M. Grande
   
   
9. UK Government Recommendations on Vaccinating Children - Ages 12-15
   
   
10. Comparison of children and young people admitted with SARS-CoV-2 across the UK in the first and second pandemic waves: prospective multicentre observational cohort study, Semple et al.
    
    
11. Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum, Stuart P. Weisberg, Thomas J. Connors, Donna L. Farber
    
    
12. Open Schools, Covid-19, and Child and Teacher Morbidity in Sweden, Jonas F. Ludvigsson, Lars Engerström, Charlotta Nordenhäll, Emma Larsson
    
    
13. Transient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA Vaccine, Ori Snapiri, Chen Rosenberg Danziger, Nina Shirman, Avichai Weissbach, Alexander Lowenthal, Itay Ayalon, Dganit Adam, Havatzelet Yarden-Bilavsky, Efraim Bilavsky
    
    
14. Myocarditis following COVID-19 mRNA vaccination, Saif Abu Mouch, Ariel Roguin, Elias Hellou, Amorina Ishai, Uri Shoshan, Lamis Mahamid, Marwan Zoabi, Marina Aisman, Nimrod Goldschmid, Noa Berar Yanay
    
    
15. Myocarditis following COVID-19 vaccination, Albert, E., Aurigemma, G., Saucedo, J., Gerson, D. S.
    
    
16. Acute Myocardial Infarction and Myocarditis following COVID-19 Vaccination, Aye, Y. N., Mai, A. S., Zhang, A., Lim, O. Z. H., Lin, N., Ng, C. H., . . . Chew, N. W. S.
    
    
17. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting, Barda, N., Dagan, N., Ben-Shlomo, Y., Kepten, E., Waxman, J., Ohana, R., . . . Balicer, R. D.
    
    
18. COVID19 Vaccine for Adolescents. Concern about Myocarditis and Pericarditis, Calcaterra, G., Mehta, J. L., de Gregorio, C., Butera, G., Neroni, P., Fanos, V., Bassareo, P.
    
    
19. Multisystem inflammatory syndrome in a male adolescent after his second Pfizer-BioNTech COVID-19 vaccine, Chai, Q., Nygaard, U., Schmidt, R. C., Zaremba, T., Moller, A. M., & Thorvig, C. M.
    
    
20. Occurrence of acute infarct-like myocarditis following COVID-19 vaccination: just an accidental co-incidence or rather vaccination-associated autoimmune myocarditis?, Chamling, B., Vehof, V., Drakos, S., Weil, M., Stalling, P., Vahlhaus, C., . . . Yilmaz, A.
    
    
21. Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far?, Das, B. B., Moskowitz, W. B., Taylor, M. B., Palmer, A.
    
    
22. Biopsy-proven lymphocytic myocarditis following first mRNA COVID-19 vaccination in a 40-year-old male: case report, Ehrlich, P., Klingel, K., Ohlmann-Knafo, S., Huttinger, S., Sood, N., Pickuth, D., & Kindermann, M.
    
23. Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following Pfizer-BioNTech COVID-19 vaccination, Ioannou, A.
    
    
24. Myocarditis Following COVID-19 Vaccination, Isaak, A., Feisst, A., & Luetkens, J. A.
    
    
25. Myocarditis following COVID-19 vaccination, Kaul, R., Sreenivasan, J., Goel, A., Malik, A., Bandyopadhyay, D., Jin, C., . . . Panza, J. A.
    
    
26. Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination, Kim, H. W., Jenista, E. R., Wendell, D. C., Azevedo, C. F., Campbell, M. J., Darty, S. N., . . . Kim, R. J.
    
    
27. Cardiac Imaging of Acute Myocarditis Following COVID-19 mRNA Vaccination, Kim, I. C., Kim, H., Lee, H. J., Kim, J. Y., & Kim, J. Y.
    
    
28. Why are we vaccinating children against COVID-19?, Kostoff, R. N., Calina, D., Kanduc, D., Briggs, M. B., Vlachoyiannopoulos, P., Svistunov, A. A., & Tsatsakis, A.
    
    
29. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination, Lee, E. J., Cines, D. B., Gernsheimer, T., Kessler, C., Michel, M., Tarantino, M. D., . . . Bussel, J. B.
    
    
30. Myocarditis following COVID-19 vaccination - A case series, Levin, D., Shimon, G., Fadlon-Derai, M., Gershovitz, L., Shovali, A., Sebbag, A., . . . Gordon, B.
    
    
31. Vaccine advisory committee must be more transparent about decisions, Mahase, E.
    
    
32. COVID vaccines cut the risk of transmitting Delta - but not for long, Mallapaty, S.
    
    
33. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel, Mevorach, D., Anis, E., Cedar, N., Bromberg, M., Haas, E. J., Nadir, E., . . . Alroy-Preis, S.
    
    
34. COVID-19 Vaccine-Induced Thrombosis and Thrombocytopenia: First Confirmed Case from India, Mishra, K., Barki, S., Pattanayak, S., Shyam, M., Sreen, A., Kumar, S., & Kotwal, J.
    
    
35. Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis following mRNA COVID-19 vaccination: a case series, Patel, Y. R., Louis, D. W., Atalay, M., Agarwal, S., & Shah, N. R.
    
    
36. A Report on Myocarditis Adverse Events in the U.S. Vaccine Adverse Events Reporting System (VAERS) in Association with COVID-19 Injectable Biological Products, Rose, J., & McCullough, P. A.
    
    
37. Transient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA COVID-19 Vaccine, Snapiri, O., Rosenberg Danziger, C., Shirman, N., Weissbach, A., Lowenthal, A., Ayalon, I., . . . Bilavsky, E., Witberg, G., Barda, N., Hoss, S., Richter, I., Wiessman, M., Aviv, Y., . . . Kornowski, R.

Durable Natural Immunity

1. One-year sustained cellular and humoral immunities of COVID-19 convalescents, Jie Zhang, Hao Lin, Beiwei Ye, Min Zhao, Jianbo Zhan, et al.
   
   
2. Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections, Sivan Gazit, Roei Shlezinger, Galit Perez, Roni Lotan, Asaf Peretz, Amir Ben-Tov, Dani Cohen, Khitam Muhsen, Gabriel Chodick, Tal Patalon.
   
   
3. Shedding of Infectious SARS-CoV-2 Despite Vaccination, Kasen K. Riemersma, Brittany E. Grogan, Amanda Kita-Yarbro, Gunnar E. Jeppson, David H. O’Connor, Thomas C. Friedrich, Katarina M. Grande
   
   
4. Necessity of COVID-19 vaccination in previously infected individuals, Nabin K. Shrestha, Patrick C. Burke, Amy S. Nowacki, Paul Terpeluk, Steven M. Gordon
   
   
5. Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection, Ariel Israel, Yotam Shenhar, Ilan Green, Eugene Merzon, Avivit Golan-Cohen, Alejandro A Schäffer, Eytan Ruppin, Shlomo Vinker, Eli Magen.
   
   
6. Discrete Immune Response Signature to SARS-CoV-2 mRNA Vaccination Versus Infection, Ellie Ivanova, Joseph Devlin, et al.
   
   
7. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans, Jackson S. Turner, Wooseob Kim, Elizaveta Kalaidina, Charles W. Goss, Adriana M. Rauseo, Aaron J. Schmitz, Lena Hansen, Alem Haile, Michael K. Klebert, Iskra Pusic, Jane A. O’Halloran, Rachel M. Presti, Ali H. Ellebedy.
   
   
8. Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells, Kristen W. Cohen, Susanne L. Linderman, Zoe Moodie, Julie Czartoski, Lilin Lai, Grace Mantus, Carson Norwood, Lindsay E. Nyhoff, Venkata Viswanadh Edara, et al.
   
9. Incidence of Severe Acute Respiratory Syndrome Coronavirus-2 infection among previously infected or vaccinated employees, N Kojima, A Roshani, M Brobeck, A Baca, JD Klausner
   
   
10. Single cell profiling of T and B cell repertoires following SARS-CoV-2 mRNA vaccine, Suhas Sureshchandra, Sloan A. Lewis, Brianna Doratt, Allen Jankeel, Izabela Ibraim, Ilhem Messaoudi
    
    
11. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection, Jennifer M. Dan, Jose Mateus, Yu Kato, Kathryn M. Hastie, et al.
    
    
12. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status, Jason Neidleman, Xiaoyu Luo, Matthew McGregor, Guorui Xie, Victoria Murray, Warner C. Greene, Sulggi A. Lee, Nadia R. Roan.
    
    
13. Persistence of neutralizing antibodies a year after SARS-CoV-2 infection, Anu Haveri, Nina Ekström, Anna Solastie, Camilla Virta, Pamela Österlund, Elina Isosaari, Hanna Nohynek, Arto A. Palmu, Merit Melin.
    
    
14. Quantifying the risk of SARS‐CoV‐2 reinfection over time, Eamon O Murchu, Paula Byrne, Paul G. Carty, et al.
    
    
15. SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy, Laith J. Abu-Raddad, Hiam Chemaitelly, Peter Coyle, Joel A. Malek.
    
    
16. Natural immunity against COVID-19 significantly reduces the risk of reinfection: findings from a cohort of sero-survey participants, Bijaya Kumar Mishra, Debdutta Bhattacharya, Jaya Singh Kshatri, Sanghamitra Pati
    
    
17. Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from Israel, Yair Goldberg, Micha Mandel, Yonatan Woodbridge, Ronen Fluss, Ilya Novikov, Rami Yaari, Arnona Ziv, Laurence Freedman, Amit Huppert, et al.
    
    
18. Immune Memory in Mild COVID-19 Patients and Unexposed Donors Reveals Persistent T Cell Responses After SARS-CoV-2 Infection, Asgar Ansari, Rakesh Arya, Shilpa Sachan, Someshwar Nath Jha, Anurag Kalia, Anupam Lall, Alessandro Sette, et al.
    
    
19. Live virus neutralisation testing in convalescent patients and subjects vaccinated against 19A, 20B, 20I/501Y.V1 and 20H/501Y.V2 isolates of SARS-CoV-2, Claudia Gonzalez, Carla Saade, Antonin Bal, Martine Valette, et al.
    
    
20. SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T cells, Jae Hyung Jung, Min-Seok Rha, Moa Sa, Hee Kyoung Choi, Ji Hoon Jeon, et al, Nature Communications.
    
    
21. Antibody Evolution after SARS-CoV-2 mRNA Vaccination, Alice Cho, Frauke Muecksch, Dennis Schaefer-Babajew, Zijun Wang, et al.
    
    
22. Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naïve and COVID-19 recovered individuals, Carmen Camara, Daniel Lozano-Ojalvo, Eduardo Lopez-Granados. et al.
    
    
23. Anti-spike antibody response to natural SARS-CoV-2 infection in the general population, ​​Jia Wei, Philippa C. Matthews, Nicole Stoesser, et al.
    
    
24. SARS-CoV-2 Natural Antibody Response Persists for at Least 12 Months in a Nationwide Study From the Faroe Islands, Maria Skaalum Petersen, Cecilie Bo Hansen, Marnar Fríheim Kristiansen, et al.
    
    
25. Secondary household transmission of SARS-CoV-2 among children and adolescents: clinical and epidemiological aspects, Afonso, E. T., Marques, S. M., Costa, L. D. C., Fortes, P. M., Peixoto, F., Bichuetti-Silva, D. C., . . . Guimaraes, R. A.
    
    
26. The role of children and adolescents in the transmission of SARS-CoV-2 virus within family clusters: A large population study from Oman, Alqayoudhi, A., Al Manji, A., Al Khalili, S., Al Maani, A., Alkindi, H., Alyaquobi, F., . . . Al-Abri, S.
    
    
27. A school outbreak of pandemic (H1N1) 2009 infection: assessment of secondary household transmission and the protective role of oseltamivir, Leung, Y. H., Li, M. P., & Chuang, S. K.
    
    
28. Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate, Madewell, Z. J., Yang, Y., Longini, I. M., Jr., Halloran, M. E., and Dean, N. E.
    
    
29. Can children of the Sputnik V vaccine recipients become symptomatic?, Mehraeen, E., SeyedAlinaghi, S., and Karimi, A. 

Effective Early Treatment

1. A Comparative Study on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin Therapy on COVID-19 Patients, Abu Taiub Mohammed Mohiuddin Chowdhury, Mohammad Shahbaz, Md Rezaul Karim, Jahirul Islam, Guo Dan, Shuixiang He
   
   
2. Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study, Matthew S Freiberg, et al
   
   
3. Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial, Reaz, Mahmud, Rahman, Mujibur, Iftikher, Alam, Ahmed, Kazi Gias Uddin, Kabir, A. K. M. Humayon, S. K. Jakaria Been, Mohammad Aftab, Mohammad Monirul, Anindita Das, Mohammad Mahfuzul, Mohammad Abdullah, Mohammad Zaid
   
   
4. The Role of Steroids in the Management of COVID-19 InfectionZayar Lin, Wai Hnin Phyu, Zin Hnin Phyu, and Tin Zar Mon
   
   
5. Antithrombotic Therapy to Ameliorate Complications of COVID-19, Brett L Houston et al
   
   
6. COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study, Roland Derwand, Martin Scholz, Vladimir Zelenko
   
   
7. Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19, Saiful Islam Kha, Sakirul Islam Khan, Chitto Ranjan Debnath, Progga Nanda Nath, Mamun Al Mahtab, Hiroaki Nabeka, Seiji Matsuda, Sheikh Mohammad Fazle Akbar
   
   
8. Ivermectin and the odds of hospitalization due to COVID-19: evidence from a quasi-experimental analysis based on a public intervention in Mexico City, Jose Merino, Victor Hugo Borja, Oliva Lopez, José Alfredo Ochoa, Eduardo Clark, Lila Petersen, Saul Caballero
   
   
9. Evaluation of Ivermectin as a Potential Treatment for Mild to Moderate COVID-19: A Double-Blind Randomized Placebo Controlled Trial in Eastern India, Ravikirti, Roy, R., Pattadar, C., Raj, R., Agarwal, N., Biswas, B., Manjhi, P. K., Rai, D. K., Shyama, Kumar, A., & Sarfaraz, A.
   
   
10. Hydroxychloroquine for prophylaxis and treatment of COVID-19 in health-care workers, Simova T., Vekov J., Krasnaliev V., Kornovski P., Bozhinov
    
    
11. Efficacy of a Low Dose of Melatonin… in Hospitalized Patients with COVID-19, GholamHossein Alishiri
    
    
12. The ten reasons why corticosteroid therapy reduces mortality in severe COVID-19, Yaseen M. Arabi, George P. Chrousos & G. Umberto Meduri
    
    
13. Early short course corticosteroids in hospitalized patients with COVID-19 (Multi-center quasi-experimental study), Mayur S Ramesh et al.
    
    
14. Doxycycline and Hydroxychloroquine as Treatment for High-Risk COVID-19 Patients: Experience from Case Series of 54 Patients in Long-Term Care Facilities, Ahmad I et al.
    
    
15. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19. A Randomized Clinical Trial, Lenze E et al.
    
    
16. Possible Therapeutic Effects of Adjuvant Quercetin Supplementation Against Early-Stage COVID-19 Infection: A Prospective, Randomized, Controlled, and Open-Label Study, Di Pierro F et al.
    
    
17. Antivirals With Adjunctive Corticosteroids Prevent Clinical Progression of Early Coronavirus 2019 Pneumonia: A Retrospective Cohort Study, Ooi ST et al.
    
    
18. Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients, Carlucci P et al.
    
    
19. SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels, Kaufman H et al.
    
    
20. Hydroxychloroquine and Azithromycin Treatment of Hospitalized Patients Infected with SARS-CoV-2 in Senegal from March to October 2020, Taieb F et al.
    
    
21. Doxycycline and Hydroxychloroquine as Treatment for High-Risk COVID-19 Patients: Experience from Case Series of 54 Patients in Long-Term Care Facilities, Ahmad I et al.
    
    
22. Hydroxychloroquine in Early Treatment of High-Risk COVID-19 Outpatients: Efficacy and Safety Evidence, Risch, Harvey.
    
    
23. Metaanalyses and Aggregated Ivermectin Studies - 1
    
    
24. Metaanalyses and Aggregated Hydroxychloroquin Studies - 1
    
    
25. Metaanalyses and Aggregated Ivermectin Studies - 2